ARTICLE | Market Access
Organization’s latest paper is a user guide to assess drug value
By Richard Guy, Biopharma Analyst
November 25, 2024 4:41 PM UTC
In an attempt to encourage wider implementation of its cost-effectiveness analysis methodology, No Patient Left Behind has published a guide that explains how to use it.
The paper, published Nov. 8 in Forum for Health Economics & Policy, asserts that drug value should be assessed using a method called the Generalized Cost-Effectiveness Analysis (GCEA) framework, which incorporates value elements such as disease severity, price declines due to the loss of market exclusivity, and the social value that accrues as a drug is used to treat successive cohorts of patients, all of which are overlooked by traditional methods. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/653169/no-patient-left-behind-pushing-alternative-cost-effectiveness-method